Chinook Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Chinook Therapeutics, a biopharmaceutical firm focused on kidney diseases, will present at the 2022 Bloom Burton & Co. Healthcare Investor Conference on May 2, 2022, at 10:00 am ET in Toronto. The event will include 1x1 meetings with management. Interested investors can access a live webcast and archived recordings through Chinook’s official website, available for replay for 90 days following the event. Chinook is developing precision medicines, including atrasentan for IgA nephropathy and other chronic kidney disorders, as part of its commitment to advancing treatment options.
- None.
- None.
SEATTLE, April 25, 2022 (GLOBE NEWSWIRE) -- Chinook Therapeutics, Inc. (Nasdaq: KDNY), a biopharmaceutical company focused on the discovery, development and commercialization of precision medicines for kidney diseases, today announced that Chinook management is scheduled to present and participate in 1x1 meetings at the 2022 Bloom Burton & Co. Healthcare Investor Conference in Toronto, Ontario on Monday, May 2, 2022 at 10:00 am ET.
To access the live webcast and subsequent archived recording of this and other company presentations, please visit the Investors section of Chinook’s website. The archived webcasts will remain available for replay on Chinook’s website for 90 days.
About Chinook Therapeutics, Inc.
Chinook Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing precision medicines for kidney diseases. Chinook’s product candidates are being investigated in rare, severe chronic kidney disorders with opportunities for well-defined clinical pathways. Chinook’s lead program is atrasentan, a phase 3 endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. BION-1301, an anti-APRIL monoclonal antibody is being evaluated in a phase 1/2 trial for IgA nephropathy. CHK-336, an oral small molecule LDHA inhibitor for the treatment of hyperoxalurias, is being evaluated in a phase 1 healthy volunteer trial. In addition, Chinook is advancing research programs for other rare, severe chronic kidney diseases. Chinook is building its pipeline by leveraging insights in kidney single cell RNA sequencing, human-derived organoids and new translational models, to discover and develop therapeutics with differentiating mechanisms of action against key kidney disease pathways. To learn more, visit www.chinooktx.com.
FAQ
When is Chinook Therapeutics presenting at the 2022 Bloom Burton & Co. Conference?
Where can I watch the Chinook Therapeutics presentation from the conference?
What is the focus of Chinook Therapeutics?
What is the lead program of Chinook Therapeutics?
What are some other candidates being developed by Chinook?
